More: 15th Conference on Retroviruses and Opportunistic Infections (CROI)

CROI 2008: Emerging Strategies in Antiretroviral Therapy: Clinical Trials in Naïve and Experienced Patients CME

February 3 - 6, 2008, Boston, Massachusetts

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the 15th Conference on Retroviruses and Opportunistic Infections.

Release Date: February 27, 2008; Valid for credit through February 27, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 15th Conference on Retroviruses and Opportunistic Infections. These materials and the related activity are not sanctioned by the 15th Conference on Retroviruses and Opportunistic Infections or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Merck
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe new data relevant to the management of patients with HIV infection who have limited or no drug-treatment experience
  2. Review emerging data on strategies to optimize the management of treatment-experienced patients with HIV infection
Authors and Disclosures

Eric S. Daar, MD
Disclosure: Eric S. Daar, MD, has disclosed that he has received grants for clinical research from Abbott, GlaxoSmithKline, Gilead, and Merck. Dr. Daar has also disclosed that he has received grants for educational activities from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Merck, Monogram, Pfizer, Tibotec, and Virco, and that he has served as an advisor or consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Merck, Monogram, Pfizer, Tibotec, and Virco.


Edwin DeJesus, MD, FACP
Disclosure: Edwin DeJesus, MD, FACP, has disclosed that he has received grant and research support from Roche and Gilead. Dr. DeJesus has also disclosed that he has served as a consultant or on the advisory board for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Roche, and Vertex.


Thomas Maxwell Mundy, MD
Disclosure: Thomas Maxwell Mundy, MD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.